150 related articles for article (PubMed ID: 31423337)
1. Interim analysis of a real-world precision medicine platform for molecular profiling of metastatic or advanced cancers: MONDTI.
Kieler M; Unseld M; Bianconi D; Waneck F; Mader R; Wrba F; Fuereder T; Marosi C; Raderer M; Staber P; Berger W; Sibilia M; Polterauer S; Müllauer L; Preusser M; Zielinski CC; Prager GW
ESMO Open; 2019; 4(4):e000538. PubMed ID: 31423337
[TBL] [Abstract][Full Text] [Related]
2. Targeted Therapy Recommendations for Therapy Refractory Solid Tumors-Data from the Real-World Precision Medicine Platform MONDTI.
Taghizadeh H; Unseld M; Spalt M; Mader RM; Müllauer L; Fuereder T; Raderer M; Sibilia M; Hoda MA; Aust S; Polterauer S; Lamm W; Bartsch R; Preusser M; A KW; Prager GW
J Pers Med; 2020 Oct; 10(4):. PubMed ID: 33114048
[TBL] [Abstract][Full Text] [Related]
3. Molecular Guided Treatments in Gynecologic Oncology: Analysis of a Real-World Precision Cancer Medicine Platform.
Taghizadeh H; Mader RM; Müllauer L; Aust S; Polterauer S; Kölbl H; Seebacher V; Grimm C; Reinthaller A; Prager GW
Oncologist; 2020 Jul; 25(7):e1060-e1069. PubMed ID: 32369643
[TBL] [Abstract][Full Text] [Related]
4. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
[TBL] [Abstract][Full Text] [Related]
5. Applied precision cancer medicine in metastatic biliary tract cancer.
Taghizadeh H; Müllauer L; Mader R; Prager GW
Hepatol Int; 2020 Mar; 14(2):288-295. PubMed ID: 32100259
[TBL] [Abstract][Full Text] [Related]
6. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
[TBL] [Abstract][Full Text] [Related]
7. Analysis of 10 Adrenocortical Carcinoma Patients in the Cohort of the Precision Medicine Platform MONDTI.
Kieler M; Müllauer L; Koperek O; Bianconi D; Unseld M; Raderer M; Prager GW
Oncology; 2018; 94(5):306-310. PubMed ID: 29444511
[TBL] [Abstract][Full Text] [Related]
8. The Molecular Landscape of Recurrent and Metastatic Head and Neck Cancers: Insights From a Precision Oncology Sequencing Platform.
Morris LGT; Chandramohan R; West L; Zehir A; Chakravarty D; Pfister DG; Wong RJ; Lee NY; Sherman EJ; Baxi SS; Ganly I; Singh B; Shah JP; Shaha AR; Boyle JO; Patel SG; Roman BR; Barker CA; McBride SM; Chan TA; Dogan S; Hyman DM; Berger MF; Solit DB; Riaz N; Ho AL
JAMA Oncol; 2017 Feb; 3(2):244-255. PubMed ID: 27442865
[TBL] [Abstract][Full Text] [Related]
9. Personalized comprehensive molecular profiling of high risk osteosarcoma: Implications and limitations for precision medicine.
Subbiah V; Wagner MJ; McGuire MF; Sarwari NM; Devarajan E; Lewis VO; Westin S; Kato S; Brown RE; Anderson P
Oncotarget; 2015 Dec; 6(38):40642-54. PubMed ID: 26510912
[TBL] [Abstract][Full Text] [Related]
10. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
Shea M; Costa DB; Rangachari D
Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
[TBL] [Abstract][Full Text] [Related]
11. Precision Medicine for the Management of Therapy Refractory Colorectal Cancer.
Taghizadeh H; Mader RM; Müllauer L; Erhart F; Kautzky-Willer A; Prager GW
J Pers Med; 2020 Dec; 10(4):. PubMed ID: 33322358
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive molecular profiling broadens treatment options for breast cancer patients.
Kawaji H; Kubo M; Yamashita N; Yamamoto H; Kai M; Kajihara A; Yamada M; Kurata K; Kaneshiro K; Harada Y; Hayashi S; Shimazaki A; Mori H; Akiyoshi S; Oki E; Oda Y; Baba E; Mori M; Nakamura M
Cancer Med; 2021 Jan; 10(2):529-539. PubMed ID: 33274848
[TBL] [Abstract][Full Text] [Related]
13. Molecular Tumour Board (MTB): From Standard Therapy to Precision Medicine.
Ballatore Z; Bozzi F; Cardea S; Savino FD; Migliore A; Tarantino V; Chiodi N; Ambrosini E; Bianchi F; Goteri G; Filosa A; Barbisan F; Bartoli E; Papa R; Berardi R
J Clin Med; 2023 Oct; 12(20):. PubMed ID: 37892804
[No Abstract] [Full Text] [Related]
14. Spatio-temporal mutation profiles of case-matched colorectal carcinomas and their metastases reveal unique de novo mutations in metachronous lung metastases by targeted next generation sequencing.
Kovaleva V; Geissler AL; Lutz L; Fritsch R; Makowiec F; Wiesemann S; Hopt UT; Passlick B; Werner M; Lassmann S
Mol Cancer; 2016 Oct; 15(1):63. PubMed ID: 27756406
[TBL] [Abstract][Full Text] [Related]
15. Actionable molecular alterations in advanced gynaecologic malignancies: updated results from the ProfiLER programme.
Varnier R; Le Saux O; Chabaud S; Garin G; Sohier E; Wang Q; Paindavoine S; Pérol D; Baudet C; Attignon V; Pissaloux D; Heudel P; You B; Leyronnas C; Collard O; Trédan O; Bonnin N; Long J; Jacquin JP; Cassier PA; Derbel O; Freyer G; Viari A; Blay JY; Ray-Coquard I
Eur J Cancer; 2019 Sep; 118():156-165. PubMed ID: 31351267
[TBL] [Abstract][Full Text] [Related]
16. A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: implications for clinical practice.
Vasan N; Yelensky R; Wang K; Moulder S; Dzimitrowicz H; Avritscher R; Wang B; Wu Y; Cronin MT; Palmer G; Symmans WF; Miller VA; Stephens P; Pusztai L
Oncologist; 2014 May; 19(5):453-8. PubMed ID: 24710307
[TBL] [Abstract][Full Text] [Related]
17. Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study.
Zivanovic Bujak A; Weng CF; Silva MJ; Yeung M; Lo L; Ftouni S; Litchfield C; Ko YA; Kuykhoven K; Van Geelen C; Chandrashekar S; Dawson MA; Loi S; Wong SQ; Dawson SJ
PLoS Med; 2020 Oct; 17(10):e1003363. PubMed ID: 33001984
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor pathway mutation and expression profiles in cervical squamous cell carcinoma: therapeutic implications.
Bumrungthai S; Munjal K; Nandekar S; Cooper K; Ekalaksananan T; Pientong C; Evans MF
J Transl Med; 2015 Jul; 13():244. PubMed ID: 26209091
[TBL] [Abstract][Full Text] [Related]
19. Clinical management of molecular alterations identified by high throughput sequencing in patients with advanced solid tumors in treatment failure: Real-world data from a French hospital.
Pinet S; Durand S; Perani A; Darnaud L; Amadjikpe F; Yon M; Darbas T; Vergnenegre A; Egenod T; Simonneau Y; Le Brun-Ly V; Pestre J; Venat L; Thuillier F; Chaunavel A; Duchesne M; Fermeaux V; Guyot A; Lacorre S; Bessette B; Lalloué F; Durand K; Deluche E
Front Oncol; 2023; 13():1104659. PubMed ID: 36923436
[TBL] [Abstract][Full Text] [Related]
20. Applied Precision Cancer Medicine in Neuro-Oncology.
Taghizadeh H; Müllauer L; Furtner J; Hainfellner JA; Marosi C; Preusser M; Prager GW
Sci Rep; 2019 Dec; 9(1):20139. PubMed ID: 31882734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]